Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

Pugliatti, 2006, The epidemiology of multiple sclerosis in Europe, Eur J Neurol, 13, 700, 10.1111/j.1468-1331.2006.01342.x Compston, 2008, Multiple sclerosis, Lancet, 372, 1502, 10.1016/S0140-6736(08)61620-7 Coles, 2008, Alemtuzumab vs interferon beta-1a in early multiple sclerosis, N Engl J Med, 359, 1786, 10.1056/NEJMoa0802670 Kappos, 2007, Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study, Lancet, 370, 389, 10.1016/S0140-6736(07)61194-5 Coles, 2006, The curious incident of disability in multiple sclerosis trials, Lancet Neurol, 5, 899, 10.1016/S1474-4422(06)70585-3 Pittenger, 1999, Multilineage potential of adult human mesenchymal stem cells, Science, 284, 143, 10.1126/science.284.5411.143 Arthur, 2009, The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair, J Cell Physiol, 218, 237, 10.1002/jcp.21592 Uccelli, 2011, Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases, Lancet Neurol, 10, 649, 10.1016/S1474-4422(11)70121-1 Payne, 2011, The prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis, Curr Stem Cell Res Ther, 6, 50, 10.2174/157488811794480735 Zappia, 2005, Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy, Blood, 106, 1755, 10.1182/blood-2005-04-1496 Zhang, 2006, Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice, J Neurosci Res, 84, 587, 10.1002/jnr.20962 Bai, 2009, Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis, Glia, 57, 1192, 10.1002/glia.20841 Gerdoni, 2007, Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis, Ann Neurol, 61, 219, 10.1002/ana.21076 Kassis, 2008, Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis, Arch Neurol, 65, 753, 10.1001/archneur.65.6.753 Le Blanc, 2008, Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study, Lancet, 371, 1579, 10.1016/S0140-6736(08)60690-X Sun, 2009, Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans, Stem Cells, 27, 1421, 10.1002/stem.68 Carrion, 2010, Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients, Lupus, 19, 317, 10.1177/0961203309348983 Mohyeddin Bonab, 2007, Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study, Iran J Immunol, 4, 50 Yamout, 2010, Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study, J Neuroimmunol, 227, 185, 10.1016/j.jneuroim.2010.07.013 Karussis, 2010, Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis, Arch Neurol, 67, 1187, 10.1001/archneurol.2010.248 Mehta, 2009, Proof of concept studies for tissue-protective agents in multiple sclerosis, Mult Scler, 15, 542, 10.1177/1352458508101939 Kolappan, 2009, Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis, J Neurol, 256, 305, 10.1007/s00415-009-0123-z Connick, 2011, The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments, Trials, 12, 62, 10.1186/1745-6215-12-62 Poser, 1983, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, 13, 227, 10.1002/ana.410130302 Dominici, 2006, Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy, 8, 315, 10.1080/14653240600855905 Johnson, 2006, Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells, Lab Invest, 86, 968, 10.1038/labinvest.3700441 Oberg, 2007, Linear mixed effects models, Methods Mol Biol, 404, 213, 10.1007/978-1-59745-530-5_11 Lublin, 1996, Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology, 46, 907, 10.1212/WNL.46.4.907 Barkhof, 2003, Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance, Arch Neurol, 60, 1073, 10.1001/archneur.60.8.1073 Schmierer, 2004, Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain, Ann Neurol, 56, 407, 10.1002/ana.20202 Franklin, 2008, Remyelination in the CNS: from biology to therapy, Nat Rev Neurosci, 9, 839, 10.1038/nrn2480 Rivera, 2006, Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells, Stem Cells, 24, 2209, 10.1634/stemcells.2005-0614 Bai, 2007, Human mesenchymal stem cells signals regulate neural stem cell fate, Neurochem Res, 32, 353, 10.1007/s11064-006-9212-x